Furthermore, the Kaplan-Meier analysis indicated that MRPS16 mRNA expression levels were significantly associated with poorer disease-free survival (DFS) and overall survival (OS) in glioma patients (Fig. 1F and 1G). This evidence concerns the gene MRPS16 and central nervous system cancer.